Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
about
P1343
Antiproliferative and antiplasmodial dimeric phloroglucinols from Mallotus oppositifolius from the Madagascar Dry Forest (1)Anti-cancer effect of HIV-1 viral protein R on doxorubicin resistant neuroblastomaResveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell linesKallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft modelFuroquinoline alkaloids of Ertela (Monnieria) trifolia (L.) Kuntze from the Suriname rainforestBioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.Bioactive isomalabaricane triterpenoids from Rhabdastrella globostellata that stabilize the binding of DNA polymerase beta to DNA.Dynamic telomerase gene suppression via network effects of GSK3 inhibitionSaponins and a lignan derivative of Terminalia tropophylla from the Madagascar Dry Forest.Euphane triterpenoids of Cassipourea lanceolata from the Madagascar rainforestAntiproliferative cardenolide glycosides of Elaeodendron alluaudianum from the Madagascar Rainforest.The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment.Antiproliferative bistramides from Trididemnum cyclops from Madagascar (1).Two new cytotoxic naphthoquinones from Mendoncia cowanii from the rainforest of MadagascarAntiproliferative triterpenoid saponins of Dodonaea viscosa from the Madagascar dry forest.Stem cell pathways contribute to clinical chemoresistance in ovarian cancerEnhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells.Antiproliferative compounds from Pongamiopsis pervilleana from the Madagascar Dry ForestOptimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters.Four diphenylpropanes and a cycloheptadibenzofuran from Bussea sakalava from the Madagascar dry forestFrap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor geneCardenolides of Leptadenia madagascariensis from the Madagascar dry forest.Cancer chemotherapy: new strategies for success.Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.Isolation and synthesis of antiproliferative eupolauridine alkaloids of Ambavia gerrardii from the Madagascar Dry Forest.Antiproliferative and antimalarial sesquiterpene lactones from Piptocoma antillana from Puerto Rico.A new bioactive diterpene glycoside from Molinaea retusa from the Madagascar dry forest.Antiproliferative compounds of Cyphostemma greveana from a Madagascar dry forest.Astrotricoumarin, an antiproliferative 4'-hydroxy-2',3'-dihydroprenylated methylcoumarin from an Astrotrichilia sp. from the Madagascar dry forest.Antiplasmodial and antiproliferative pseudoguaianolides of Athroisma proteiforme from the Madagascar Dry Forest.Neolignans and other metabolites from Ocotea cymosa from the Madagascar rain forest and their biological activities.Bioactive oleanane glycosides from Polyscias duplicata from the Madagascar dry forest.Antiproliferative Compounds from Ocotea macrocarpa from the Madagascar Dry Forest(1).Antimalarial 5,6-Dihydro-α-pyrones from Cryptocarya rigidifolia: Related Bicyclic Tetrahydro-α-Pyrones Are Artifacts1.Antiproliferative Trihydroxyalkylcyclohexenones from Pleiogynium timoriense.Antiproliferative Compounds from Cleistanthus boivinianus from the Madagascar Dry Forest.Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexesSmoothened antagonists reverse taxane resistance in ovarian cancer.
P2860
Q24599694-613ED1FF-70AA-4DB5-854C-94844FCC080EQ28474789-0371EEB6-12DD-459B-AF5B-493090D02E8BQ28539044-09ADEE91-85CB-4256-9B88-436555E3FD65Q28742738-7EF8F834-55D0-4250-BDF2-D06671AB9C62Q29353940-978826D1-C438-4AB3-8922-3E135A59C33BQ30436347-F2EA7582-54B5-4B34-B6F5-32F9796C0D37Q30440654-C733D46E-3647-4EA1-B12B-E83E5EEE5176Q33489588-CCDF7D20-0B7C-4EA6-8854-98F4D887B5F4Q33620993-245DEA80-4367-478B-ACA0-C37F36D00D7EQ33759316-892289E6-BE95-4CFB-A6EC-A0318640F072Q33815523-55D7E464-6D7D-4C39-B459-64D34A2E5EE8Q33882357-490F4552-D73B-4B3E-A9E2-4F5FFA040613Q33908498-4B0864E7-62C6-4F1C-B622-A559C6555693Q33919697-183912F0-C006-4173-87B3-3E3127781D4DQ34002517-7A555719-55B7-44B5-B25E-83354E024EC9Q34024593-80460F3B-82CF-4259-82A9-2C506DCAC24EQ34091368-D4C684AE-FAF2-4D59-AC58-5225C60090AAQ34092005-4B74BC66-7EDE-4A26-82AA-A128FFEE9C6DQ34104052-F367BE40-501D-47A4-A161-F283766BF6DBQ34154764-4C13319D-BEDF-4D14-B89F-37CB0514479FQ34293696-B0612701-6927-4565-B5E2-507B1C4ABA8AQ34361550-D7E5DF81-08B6-458A-BA51-927CB3D6F131Q34389036-58CDF141-D921-42ED-AA80-8996BA782916Q34504844-5DC72C27-8F4D-426F-8420-2CC8E70BD9F4Q34545133-81829327-AC68-4EE7-9374-90473578EA85Q34638065-029F84EA-1C69-449F-AD8A-32F42218E7BDQ35011948-CCEE464A-3E6C-453A-AA16-0DF9CCD37C63Q35030568-36DB1A47-9B61-4648-B051-3272903B6D1EQ35052374-5E6C6A94-99BB-4FBD-AC89-784F60470CA2Q35076102-662DE619-0471-4AF0-9735-DC4EC68425AEQ35247796-011452C5-7969-4F21-AEA5-760621D545BDQ35473792-E5244D5E-1043-46D4-BD87-7BCDB391CEE4Q35538978-367BB691-429D-444B-A7E1-0F3A18631664Q35581268-06ABBF94-F0ED-4576-B541-4E1755F03DD3Q35664322-1CFBF9E5-44B1-4FB5-8EA5-368065581691Q35798699-489DADEF-F477-4F35-9EC5-E9C614110E89Q35897166-24EAE92F-F24B-425F-B435-6818BAF8073CQ35897170-68D2845A-1A94-4456-BB7F-0433B0ACA1C1Q35994695-0EDAFE7D-27BD-490E-9C8B-0AD288A6ABD4Q36084215-A1294DE9-29E6-4C5C-BFFD-E1A3366FD3EC
P2860
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
Radiation survival parameters ...... ion by buthionine sulfoximine.
@en
Radiation survival parameters ...... ion by buthionine sulfoximine.
@nl
type
label
Radiation survival parameters ...... ion by buthionine sulfoximine.
@en
Radiation survival parameters ...... ion by buthionine sulfoximine.
@nl
prefLabel
Radiation survival parameters ...... ion by buthionine sulfoximine.
@en
Radiation survival parameters ...... ion by buthionine sulfoximine.
@nl
P2093
P1433
P1476
Radiation survival parameters ...... ion by buthionine sulfoximine.
@en
P2093
Behrens BC
Grotzinger KR
Hamilton TC
Kinsella TJ
P304
P407
P4510
P577
1985-05-01T00:00:00Z